XBiotech

XBIT

$7.50arrow_drop_up1.48%$0.11

XBIT

$7.50

arrow_drop_up1.48%$0.11

Performance History

Key Stats
Open	$7.40
Prev. Close	$7.39
EPS	-1.16
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$225.12M
PE Ratio	-

	LOW	HIGH
Day Range	7.36	7.83
52 Week Range	3.51	9.96

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.16

Score Breakdown

There's no data available for score breakdown

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About XBiotech (XBIT)

XBiotech Inc (XBIT) is a biopharmaceutical company that specializes in the development and commercialization of antibody therapies. The company is focused on developing novel therapies for the treatment of various diseases, including cancer, cardiovascular diseases, and infectious diseases. XBiotech's proprietary True Human™ antibody technology platform allows for the production of antibodies that are identical to those naturally produced by the human immune system. This technology has the potential to revolutionize the field of antibody therapy by providing safer and more effective treatments.

XBiotech's lead product candidate is bermekimab, a monoclonal antibody that is being evaluated for the treatment of various inflammatory conditions. Bermekimab is currently being studied in Phase 2 and Phase 3 clinical trials for the treatment of hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis. XBiotech also has a number of other product candidates in its pipeline, including antibodies targeting interleukin-1 alpha, interleukin-10, and interleukin-13.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. John Simard
Headquarters: Austin
Employees: 84
Exchange: NASDAQ

Keep an eye on XBiotech

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is XBiotech 's (XBIT) price per share?

The current price per share for XBiotech (XBIT) is $7.5. The stock has seen a price change of $0.11 recently, indicating a 1.49% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for XBiotech (XBIT)?

For XBiotech (XBIT), the 52-week high is $9.96, which is 32.8% from the current price. The 52-week low is $3.51, the current price is 113.68% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is XBiotech (XBIT) a growth stock?

XBiotech (XBIT) has shown an average price growth of 0.41% over the past three years. It has received a score of 72 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying XBiotech as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is XBiotech (XBIT) stock price performance year to date (YTD)?

As of the latest data, XBiotech (XBIT) has a year-to-date price change of 72.81%. Over the past month, the stock has experienced a price change of 16.46%. Over the last three months, the change has been 23.36%. Over the past six months, the figure is 13.12%. Looking at a longer horizon, the five-year price change stands at -22.04%.

help

Is XBiotech (XBIT) a profitable company?

XBiotech (XBIT) has a net income of -$24.56M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$37.51M. Furthermore, the EBITDA is -$41.19M.

help

What is the market capitalization of XBiotech (XBIT)?

XBiotech (XBIT) has a market capitalization of $225.12M. The average daily trading volume is 31K, indicating the stock's liquidity and investor engagement.

News

Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - Long-term Forecast to 2033

Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen fortgeschrittenen Bauchspeicheldrüsenkrebs hin

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

6/19/2024

Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen fortgeschrittenen Bauchspeicheldrüsenkrebs hin

Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

6/19/2024

Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé